Serotonin.dr.asa

Dr. AMREEN SABA ATTARIYA
POST GRADUATE STUDENT
DEPT OF PHARMACOLOGY
M.R. MEDICAL COLLEGE, GULBARGA
INDIA
SEROTONIN

Outline Of Presentation
Introduction to SEROTONIN
Sources, Biosynthesis, Metabolism
Receptors in detail
Physiological & Pathophysiological roles
Drugs Acting On 5HT Receptors
Recent Advances
Summary & References
Mar 6, 2017Dr.ASA:serotonin

HISTORY
SEROTONIN -name given to vasoconstrictor substance which
appeared in serum when blood clot
Named after Latin word serumserum & Greek word tonictonic
1948– first isolation Maurice Rapport & Irvine Page*
Earlier called ENTERAMINE by VITTORIO ERSPAMER et al
Enteramine found in EC cells
In 1950 --both were shown to be 5-hydroxytryptamine
* Rapport et al

Physiologic Distribution of 5HT
10% CNS
90% GI tract
 90% ECs
 10% Neurons 5-Hydroxytryptamine

SOURCE
Venom of Wasps, Bees, scorpions
Widely distributed in invertebrates
Fruits--banana, pear, pineapple, tomato, plums, nuts

SEROTONIN is:
Neurotransmitter in CNS
Local hormone in the gut
Component of the platelet clotting process
Potent stimulant of pain and itch nerves
Central (CNS) modulator of:
Migraine
Vomiting
Mood, sleep, appetite, temperature, blood pressure

Biosynthesis and metabolism of
SEROTONIN

Serotonin Uptake
Like NA actively takes up serotonin by Serotonin
transporter - amine pump (SERT) – Na+
dependent carrier
Inhibited by SSRIs & TCAs
Stored in storage vesicles by active uptake –
Vesicular monoamine transporter (VMAT 2) –
inhibited by Reserpine

SEROTONIN TRANSPORTER[SERT]
Member of class of monoamine transporters.
Has 12 transmembrane spanning Na+-dependent
transporters
Mechanism is the transportation of Na+, Cl &
substrate intracellularly in exchange for K+ *
Location: GIT, pulmonary, peripheral
vasculature, platelets
Mar 6, 2017Dr.ASA:serotonin* Sneddon, 1973; Torres et al., 2003; Ni & Watts, 2006.

5HT REC SUBTYPES
Earlier[GADDUM &PICARELLI]
Mtype= MUSCULOTROPIC
Dtype=NEUROTROPIC
M type@ cholinergic nerve
endingscontrol release of Ach
D type @ smooth muscles
NEWER [1 to 7]
1– 1A 1B 1D
2-- 2A 2B 2C
3, 4, 5, 6, 7 Mar 6, 2017Dr.ASA:serotonin

5-HT Rec - Characters
All are GPCRs except 5-HT3
Decrease cAMP production – 5-HT1
Increase cAMP production – 5-HT4, 5-HT6, 5-HT7
Generating IP3/DAG – 5-HT2
5-HT3 – Ligand gated Na+
K+
channel – faster depolarization

5HT REC SUBTYPES

PHYSIOLOGICAL ROLE
OF 5HT

PHYSIOLOGICAL ROLE
PLATELETS
Lack Tryptophan hydroxylase cant synthesize 5HT
Take up from circulation & store
VMAT-2 mediated uptake into dense core granules
Vascular injury release 5HT 5HT binds on 2A rec on
platelets weak Platelet aggregation, augmented by Collagen
If injury reaches till smooth muscle direct release of 5HT V/s
occlusion & VC Hempostasis
5HT interaction with Endothelium release NO VD
[antgonising its own plus other local hormone action]

LOCAL INFLUENCES OF
PLATELET 5HT

PHYSIOLOGICAL ROLE
CVS
+VE IONOTROPIC, +VE CHRONOTROPIC
Contraction--splanchnic, renal, pulmonary & cerebral vasculatures
Also cause release of NO & PGs + block the release of NE from
sympatheitic nerves arterial relaxation
Other hand, amplifies the local constrictor actions of NE, AngII,
and histaminereinforce the hemostatic response to 5-HT

PHYSIOLOGICAL ROLE
CVS
Effect on BP
BEZOLD
JARISCH REFLEX
Early sharp fall
----chemoreflex.
Brief rise----
vasoconstriction
and increased CO
Prolonged fall
----arterial dilatation
& extravasation of
fluid. Mar 6, 2017Dr.ASA:serotonin

PHYSIOLOGICAL ROLE
GIT
5HT-local hormone in GITinitiation & susutainance of
intestinal peristalsis
Potent stimulator of GIT Diarrhoea
Inhibit gastric acid & pepsin, increases mucus production
ULCEROPROTECTIVE PROPERTY
Stimulates vomiting (5-HT3rec on vagal afferents &
centrally) on 5-HTrec
(Physiologically regulates GI motility and peristalsis)

5HT in GIT
Abnormally increased 5-HT is found in a range of
gastrointestinal disorders including Chemotherapy-
induced Nausea & Vomiting, Carcinoid Syndrome,
Coeliac Disease, IBD & IBS-D
IBS-D- Impaired SERTincrease in mucosal 5-HT
availability.
IBS-D -- increased 5-HT postprandially

5-HT3 rec antagonists inhibit chemotherapy-induced
nausea & diarrhoea associated with both carcinoid
syndrome & IBS.
IBS-C---impaired 5-HT response &responds to 5HT-4
agonists-PRUCALOPRIDE & 5HT-4 partial agonists-
TEGASEROD.
*Spiller R Recent advances in understanding the role of 5HT in GI motility in
functional bowel disorders: alterations in 5-HT signalling & metabolism in human
disease.Neurogastroenterol Motil. 2007 Aug;19 Suppl 2:25-31.

PHYSIOLOGICAL ROLE

PHYSIOLOGICAL ROLE
CNS
NEUROHUMORAL TRANSMISSION
5HT—released by tryptaminergic neurons
Function: Temp Regulation, Endocrine Control,
ExtraPyramidal Activity
Altered function disturbances in Sleep,
Appetite, Mood, Sexual Behaviour, Motor Activity,
Perception, Migraine

PHYSIOLOGICAL ROLE
CNS
SLEEP
5HT—control sleep-wake cycle
Depletion INSOMNIA

PHYSIOLOGICAL ROLE
CNS
BEHAVIOUR
5HT—control mood, emotion, reward, memory
Low CSF-5HIAA IMPULSIVE, VIOLENT,
SUICIDAL BEHAVIOUR
Rx= SSRI[for mental depression]
5HT rec function is altered in EATING disorders –
Anorexia Nervosa, Bulimia Nervosa

DRUGS ACTING ON 5-HT

DRUGS ACTING ON 5-HT SYSTEM
5-HT Precursor – Tryptophan in diet↑  5-HT↑
production
Inhibit synthesis: p-chlorophenylalanine (PCPA) -
irreversible
Inhibit neuronal re-uptake: Cocaine, SSRI, TCA
Inhibit storage-deplete (VMAT-2): Reserpine
Inhibit metabolism: MAO-A inhibitors
Promote release: Amphetamines

SSRIs
Fluoxetine, Fluvoxamine, Paroxetine, Sertraline,
Citalopram, Escitalopram
MOA:
Selectively block reuptake of 5HT
Increased extracellular 5HT
Increased action on postsynaptic receptors
Stimulation

 PK of SSRI:
Orally absorbed
Metabolism=liver
2D6 & 2C19
t1/2=18hrs-7d
SSRI(t1/2) DOSES
(mg/d)
Fluoxetine(2d) 10-60
Fluvoxamine(18hrs) 50-300
Paroxetine(20hrs) 10-40
Sertraline(26hrs) 50-200
Citalopram(33hrs) 10-40

AE-SSRIs
Pharmacological
Action
Adverse Effect
GIT Nausea, Vomiting, Diarrhea
Neuropsychiatry Agitation, Tremor, Insomnia
And Daytime Somnolence,
Seizures, Mania
Sexual Dysfunctions Ejaculatory Delay, Anorgasmia

SEROTONERGIC
DRUGS

SEROTONERGIC DRUGS
PARTIAL AGONIST- AZAPIRONES
AGONISTS
TRIPTANS
ERGOT & ERGOT ALKALOIDS
D-LYSERGIC ACID DIETHYLAMIDE(LSD)
ANTAGONISTS-- CYPROHEPTADINE
METHYSERGIDE
KETANSERIN
ATYPICAL ANTIPSYCHOTICS

PARTIAL AGONIST- AZAPIRONES
BUSPIRONE, GEPIRONE, IPSAPERONE
Selective partial agonists of 5HT-1A
Effective in the treatment of anxiety
Mimics antianxiety properties of BDZs but donot interact
with GABAA rec
Do not display sedative & anticonvulsant properties of
BDZs.

AGONISTS
TRIPTANS
D-LYSERGIC ACID DIETHYLAMIDE(LSD)
PROKINETICS- CISAPRIDE, MOSAPRIDE

TRIPTANS
Almotriptan, Eletriptan, Frovatriptan, Naratriptan,
Rizatriptan, Sumatriptan, Zolmitriptan
Agonist of 5-HT1D 5-HT1B
Low / no affinity for other subtypes of 5-HTrec or
for adrenergic, dopaminergic, muscarinic
cholinergic, GABAA receptors

TRIPTANS-MOA
MOA: 2 hypothesis of migraine pathophysiology
I: unknown events lead to abnormal dilation of carotid AV
anastomoses in headdiverting blood from capillary bedscerebral
ischemia & hypoxia.
Rx: Triptans constrict IC blood vessels, including AV anastomoses
& restores blood flow to brain
II: 5-HT1D & 5-HT1Bserve as presynaptic autoreceptorsmodulate
neurotransmitter release from neuronal terminals
5-HT1 agonists block the release
of proinflammatory neuropeptides

TRIPTANS-PK
SUMATRIPTAN(SC, ORAL, NASAL SPRAY)
SCpeak conc 12min,BA=97% ORAL 1-2hrs,BA14-17%
t1/2 = 1-2hrs, Metabolised by MAO-A, Excretion in urine
 ZOLMITRIPTAN(ORAL)
ORAL peak conc 1.5-2hrs, BA=40% t1/2 =2-3hrs
 NARATRIPTAN(ORAL)
ORAL peak conc 2-3hrs, BA =70% t1/2 =6hrs
 RIZATRIPTAN(ORAL)
ORAL peak conc 1-1.5hrs, BA=45%
Metabolised by MAO-A

TRIPTANS-AE
Cardiac events--coronary artery vasospasm, transient
MI,atrial & ventricular arrhythmias, MI
SC Sumatriptanirritation at the site of injection
(transient mild pain, stinging, or burning sensations).
Nasal spray Sumatriptan bitter taste.
Oralparesthesias, asthenia,fatigue,flushing, feelings of
pressure, tightness, or pain in chest,neck, & jaw;
drowsiness, dizziness, nausea, sweating.

TRIPTANS-C/I
H/o ischemic or vasospastic CAD (strokeTIA), cerebrovascular, PVD
hemiplegic or basilar migraines, other significant cardiovascular
diseases, or IBD
Uncontrolled HTN.
Naratriptan C/I-severe renal/hepatic impairment.
Rizatriptan--with caution in renal/hepatic disease but not C/I
Eletriptan C/I--hepatic disease.
Almotriptan,rizatriptan, sumatriptan, zolmitriptan are C/I in
patients who have taken MAO-I within the preceding 2 weeks
All triptans C/I--near-term prior exposure to ergot alkaloids or other
5-HT agonists Mar 6, 2017Dr.ASA:serotonin

TRIPTANS-Use in Migraine
In acute Rx of migraine (with/without aura), but not for
prophylaxis.
Begin as soon as possible after onset of a migraine attack
Oral – most convenient, but Nausea & Vomiting occurs.
SUMATRIPTAN SC=6mg(max 12mg/d), Nasal spray=5-20mg
Oral=25-100mg(max 200mg/d)
ZOLMITRIPTAN oral =1.25-2.5 mg(max10mg/d)
NARATRIPTAN oral=1-2.5 mg,should not be repeated until 4
hours after previous dose. Donot exceed 5mg/day
RIZATRIPTAN oral= 5-10 mg, max 30mg/d
Donot use concurrently with other tripans / ergot derivativesMar 6, 2017

Partial agonists/antagonists at adrenergic, dopaminergic & 5HT rec
Effects depends onagent, dosage,species, tissue, physiological &
endocrinological state, & experimental conditions.
Ergot derivative-METHYSERGIDE-2A>2C blocker—Rx of acute
migraine
Ergot for migraine should be restricted to patients having frequent,
moderate migraine / infrequent, severe migraine attacks
Ergotamine, Ergonovine, Methyl-ergonovine,
Dihydroergotamine(DHE)

ERGOTAMINE
Most effective ergot alkaloid in Migraine
MOA:
Partial agonist of 5-HT1B/1D – 1. Constriction of dilated
cranial vessels
Or, 2. by specific Constriction of carotid AV shunt
channels
3. Reduction of neurogenic inflammation
Doses: oral/SL (1mg every half an hourly) till relief – 6
mg/d
DIHYDROERGOTAMINE(DHE)
Preferred for parenteral administration

Current Status of Ergots in Migraine
Not popular anymore
Regular use is hazardous
No prophylactic value – precipitate on
discontinuation
Dull headache
Available prep=Combination with caffeine,
paracetamol etc

5HT AGONIST- LSD
D-Lysergic acid diethyl amide
Chemical precursor=lysergic acid, occurs naturally in a
fungus-that grows on wheat & rye-but is devoid of
hallucinogenic actions.
LSD has indolealkylamine moiety which interacts with 5-
HT rec
Agonist 5-HT1A marked slowing of firing in Raphe
cellbodies
Studies of 5-HT2Arec knockout mice confirm the role
for this rec in LSD hallucinogenic effects*
* Gonzalez-Maeso et al., 2007

ANTAGONISTS
CYPROHEPTADINE
METHYSERGIDE
KETANSERIN
OTHERS:ATYPICAL ANTIPSYCHOTICS
ONDANSETRON, GRANISETRON
METACHLOPRAMIDE

CYPROHEPTADINE
5-HT2Ablocking property
Weak H1 antihistaminic, anticholinergic & sedative
Famous for increasing appetite
Uses: good antipruritic – used in allergies (no 5-HT Role)
Carcinoid syndrome
Gastrectomy dumping syndrome
Priapism (caused by fluoxetine)
Appetite stimulation in children
Migraine Prophylaxis
AE: weight gain, drowsiness, dry mouth, ataxia

METHYSERGIDE
Congener of methyl-ergonovine
Related to ergot alkaloids – but without ergot like effects
Weak vasoconstrictor, oxytocic
5-HT2A/2C antagonist - also tissue specific agonistic action – also
acts on 5-HT1 receptor
Uses: Prophylaxis of Migraine & other headaches, carcinoid
syndrome, post gastrectomy dumping syndrome
ADR: Abdominal, pulmonary and endocardial FIRBOSIS
If used chronicallyRx should be interrupted for 3 weeks or
more every 6 months.

KETANSERINE
Selective 5-HT2 receptor blocker[5-HT2A > 5-HT2C]
No effects on 5-HT1, 5-HT3, or 5-HT4
Additional H1, α1 and DAergic blocking action
Antagonizes VC, platelet aggregation & airway
constriction actions of 5-HT – antihypertensive
Also in vasospastic conditions – Raynauds disease
RITANSERIN= more 2A selective

OTHER ANTAGONISTS
Clozapine: Atypical antipsychotic--5HT2A/2C
blocker – weaker dopaminergic antagonist
than typical ones – used for resistant cases of
Schizophrenia
Risperidone: 5-HT2A + D2 antagonist - similar
to clozapine – used in Schizophrenia
Ondansetron: 5-HT3 antagonist – Chemo &
radiotherapy induced vomiting

DRUG REC TYPE USE
CYPROHEPTADINE 2A ANTAGONIS
T
SEROTONIN SYNDROME
METHYSERGIDE 2A/2C ANTAGONIS
T
CARCINOID & POST-
GASTRECTOMY DUMPING
SYNDROMES.
CLOZAPINE 2A/2C ANTAGONIS
T
ANTIPSYCHOTIC
RESPERIDONE 2A ANTAGONIS
T
ANTIPSYCHOTIC
KETANSERIN 2A ANTAGONIS
T
ANTIHYPERTENSIVE

DRUG REC TYPE USE DOSE
METACLOPRAMIDE 4 AGONIST GERD
IBS
10mg TDS orally
CISAPRIDE 4 AGONIST GERD
IBS
10-20mg TDS
MOSAPRIDE 4 AGONIST GERD,
IBS
5mg TDS
ONDANSETRON 3 ANTAGONIST CINV 8mg OD orally
GRANISTERON 3 ANTAGONIST CINV 2mg orally
PALANOSETRON 3 ANTAGONIST CINV

USES
Major Depression– SSRIs like Fluoxetine, Sertraline
Obsessive compulsive disorder – SSRIs
Phobic disorders - SSRIs
PMS - SSRIs
Somatoform disorders (Hypochondriasis) - SSRIs
Post traumatic stress disorder - SSRIs
Neuropathic pain & Fibromyalgia pain
Anxiety neurosis – Azapirones(5- HT1A partial agonist)Mar 6, 2017

USES
Migraine – Triptans 5-HT 1B/1D agonist
Appetite stimulant – Cyproheptadine (5-HT2A
antagonist)
Schizophrenia – Clozapine (2A/2C antagonist)
CINV –Ondansetron (Emeset 4,8mg tabs ,2mg/ml inj in 2ml
& 4ml amps), Granisetron (Granicip 1,2mg tabs ,1mg/ml
inj in 1ml & 3ml amps) Tropisetron (5-HT 3 antagonist).
GERD – Mosaprid[Moza 2.5mg ,5mg tabs] (5-HT4
agonist )
IBS – Mosapride, Prucalopride (5-HT4 agonist)

Carcinoid Syndrome
Over 90% of the serotonin in the body is found in
enterochromaffin cells in GI tract.
Carcinoid tumor secrets serotonin and is a neoplasm of
enterochromaffin cells.
Carcinoid syndrome causes subendocardial fibroplasia and
valvular or electrical malfunction.
In patients whose tumor is not operable, a serotonin
antagonist is a useful treatment.

CARCINOID SYNDROME
Cyproheptadine is a H1 and 5-HT2blocker.
It also has antimuscarinic effects and causes sedation.
It is used in the treatment of the smooth muscle
manifestations of carcinoid tumor and in cold-induced
urticaria.

Carcinoid Syndrome
5-hydroxyindoleacetic acid (5-HIAA) is a metabolite of
serotonin.
The excretion of 5-HIAA is a measure of serotonin synthesis.
The 24-hour excretion of 5-HIAA can be used as a diagnostic
test for carcinoid tumor.
Banana contains large amounts of serotonin and must be
prohibited during such tests.

Sternbach’s criteria for serotonin
syndrome*
* Sternbach, 1991;Brown et al., 1996

Agents that have potential to induce serotonin
toxicity &
their MOA for increasing serotonin levels

RECENT ADVANCES
TANDOSPIRONE – A/k/a Metanopirone--5HT1A partial
agonist—Use--anxiolytic & antidepressant. Dose =30mg/d.
AGOMELATINE – 5HT2C antagonist & agonist at
melatonin rec. Used in depression.
NELOTANSERIN (APD-125) – selective 5HT2A inverse
agonist developed by Arena pharmaceuticals for insomnia.
PALONOSETRON (Aloxi) – approved by FDA in 2003
for IV use in preventing delayed CINV

RECENT ADVANCES
RAMOSETRON – 5HT 3 antagonist available in Japan & South
east Asian countries—used in CINV.
CILANSETRON – 5HT 3 antagonist used in IBS where diarrhoea is
the dominant symptom.
LASMIDITAN-5HT1F agonist without vasoconstriction—1F is
expresses in trigeminal nerve pathway– Rx of Migraine --mainly for
individuals with CV risk factors, CVS diseases or dissatisfied with
current therapies
Newer drugs for chronic migraine OLCEGEPANT
TELCAGEPANT

SUMMARY

References…
Sander E: 5Hydroxytryptamine and dopamine Goodman & Gilman’s The
pharmacological Basis of Therapeutics 12th
ed(335-363)
5Hydroxytryptamine :Pharmacology & Pharmacotherapeutics by R.S Satoskar,
24th
ed (333-343)
5Hydroxytryptamine,its antagonist and drug therapy: Essentials of medical
pharmacology by KD Tripathi, 7th
ed(170-181)
HL Sharma, KK Sharma. Histamine, serotonin,ergot alkoloid and bradykinin In:
HL Sharma editor. Principles of pharmacology, 2nd edn. New Delhi: Para
Publishers; 2011.
Zadeh M, et al: Serotonin: J. vet. Pharmacol. Therap. 31, 187–199, doi:
10.1111/j.1365-2885.2008.00944.x. REVIEW ARTICLE
*Spiller R Recent advances in understanding the role of 5HT in GI motility in
functional bowel disorders: alterations in 5-HT signalling & metabolism in
human disease.Neurogastroenterol Motil. 2007 Aug;19 Suppl 2:25-31.

Serotonin.dr.asa

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Serotonin.dr.asa

Similar to Serotonin.dr.asa (20)

More from Dr.Amreen Saba Attariya

More from Dr.Amreen Saba Attariya (6)

Recently uploaded

Recently uploaded (20)

Serotonin.dr.asa

Editor's Notes